Fate Therapeutics (FATE) news

Circuit breaker: CIFC (BATS) - Volatility trading pause

On October 13, 2026, trading in CIFC (BATS) was temporarily paused due to a circuit breaker mechanism designed to manage excessive volatility in the stock market. Circuit breakers are pre-defined thresholds that trigger trading halts when price movements exceed specified levels within a given…

First Tracks Biotherapeutics shares rise 13.3% premarket after positive results from celiac disease drug trial

First Tracks Biotherapeutics Inc. (NASDAQ: FTBT) reported a 13.3% increase in premarket trading on October 12, 2026, following the release of positive clinical trial results . The company announced that the drug demonstrated a favorable safety profile and showed measurable efficacy in reducing…

Fate Therapeutics appoints Jamie Harrell as senior vice president, market development & commercial operations to lead the commercialization of CAR T-cell therapies

Fate Therapeutics reports new employee inducement awards under Nasdaq listing rule 5635(C)(4)

Fate Therapeutics, Inc. (NASDAQ: FATE) announced on August 3, 2026, that it granted equity awards to newly hired non-executive employees under its Amended and Restated Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4) . On August 1, 2026, the company issued non-qualified…

Fate Therapeutics gets $15M CIRM grant for FT819 trial

Fate Therapeutics, Inc. (NASDAQ: FATE) has received a $7.9 million CIRM award to advance its FT819 clinical research for the treatment of systemic lupus erythematosus (SLE). This grant supports the company’s ongoing clinical development of FT819, an induced pluripotent stem cell (iPSC)-derived CD19…